Home Biosimilar Antibodies Others Antibody-Drug Conjugate Ladiratuzumab vedotin
For research use only. Not for use in humans.

Ladiratuzumab vedotin

Synonyms: SGN-LIV1A, Anti-LIV-1 ADC

Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas.

Ladiratuzumab vedotin

CAS No.

Click to purchase products related to Ladiratuzumab vedotin

Quality Control

Batch: D405701 Purity: 99.15% Protein concentration: 3.21mg/ml Endotoxin Level: ＜1EU/mg
99.15

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas.
References

Product Details

DAR 4.16
ADC antiody ladiratuzumab
ADC linker A proteolytically cleavable type linker
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03310957 COMPLETED Drug: ladiratuzumab vedotin|Drug: Pembrolizumab Triple Negative Breast Neoplasms Seagen Inc. 2018-02-27 PHASE1; PHASE2
NCT04032704 TERMINATED Drug: ladiratuzumab vedotin|Drug: pembrolizumab Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Non-small Cell Lung Cancer, Non-squamous; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Prostate Cancer; Melanoma Seagen Inc. 2019-10-09 PHASE2
NCT01969643 COMPLETED Drug: ladiratuzumab vedotin|Drug: Trastuzumab HER2 Positive Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Triple Negative Breast Neoplasms; HER2 Mutations Breast Neoplasms Seagen Inc. 2013-10-22 PHASE1

(data from https://clinicaltrials.gov, updated on 2025-12-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.